Antibiotics in the clinical pipeline at the end of 2015
作者： Mark S Butler , Mark AT Blaskovich , Matthew A Cooper
DOI: 10.1038/JA.2016.72
关键词:
摘要: … the FDA in February 2015 for the treatment … 2016 Allergan announced the FDA has accepted for filing the company's supplemental New Drug Application (NDA) for Avycaz, adding new …
nature.com
uq.edu.au
core.ac.uk 参考文章(228)
C Lee Ventola, The antibiotic resistance crisis: part 2: management strategies and new agents. P & T : a peer-reviewed journal for formulary management. ,vol. 40, pp. 344- 352 ,(2015)
Roy M. Anderson, Antimicrobial resistance: addressing the threat to global health. Preface. Philosophical Transactions of the Royal Society B. ,vol. 370, pp. 20140305- 20140305 ,(2015) , 10.1098/RSTB.2014.0305
Battling Drug-Resistant Bacteria Chemical & Engineering News. ,(2015) , 10.1021/CEN-09240-GOVPOL1
E Bettiol, S Harbarth, Development of new antibiotics: taking off finally? Swiss Medical Weekly. ,vol. 145, ,(2015) , 10.4414/SMW.2015.14167
Dale Dominey-Howes, Maurizio Labbate, Carolyn Michael, Why emergency management should be interested in the emergence of antibiotic resistance The Australian journal of emergency management. ,vol. 29, pp. 11- ,(2014)
Mark S Butler, Mark A Blaskovich, Matthew A Cooper, Antibiotics in the clinical pipeline in 2013 The Journal of Antibiotics. ,vol. 66, pp. 571- 591 ,(2013) , 10.1038/JA.2013.86
Hao Lu, Peter J. Tonge, Inhibitors of Fabl, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway ChemInform. ,vol. 39, ,(2008) , 10.1002/CHIN.200817241
Sheo B. Singh, Confronting the challenges of discovery of novel antibacterial agents. Bioorganic & Medicinal Chemistry Letters. ,vol. 24, pp. 3683- 3689 ,(2014) , 10.1016/J.BMCL.2014.06.053
THE CRIMES OF LEAD Chemical & Engineering News. ,vol. 92, pp. 27- 29 ,(2015) , 10.1021/CEN-09205-SCITECH1
Françoise Van Bambeke, Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy Future Microbiology. ,vol. 10, pp. 1- 13 ,(2015) , 10.2217/FMB.15.39